Literature DB >> 9597424

Haemostatic risk factors for cardiovascular diseases.

W Koenig1.   

Abstract

Strong evidence from large observational epidemiological studies links haemostatic variables to the future risk of myocardial infarction and stroke. Recent data provide further evidence for an early involvement of haemostatic parameters in atherosclerosis. So far, a variety of markers of a procoagulatory tendency e.g. elevated fibrinogen, coagulation factor VII, factor VIII and von Willebrand factor, platelet hyperaggregation, increased plasma levels of D-dimer, and decreased fibrinolytic capacity, e.g. characterized by increased levels of PAI-1 activity and decreased t-PA concentrations have been identified prospectively. Thus, a complex disturbed haemostatic system plays an important role in the development of atherothrombotic events in several vascular beds. This review discusses the epidemiologic evidence of the association between the haemostatic system and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597424

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Neovascularization and angiogenic gene expression following chronic arsenic exposure in mice.

Authors:  Nicole V Soucy; Debra Mayka; Linda R Klei; Antonia A Nemec; John A Bauer; Aaron Barchowsky
Journal:  Cardiovasc Toxicol       Date:  2005       Impact factor: 3.231

2.  Regulation of Hemostasis by the Sympathetic Nervous System: Any Contribution to Coronary Artery Disease?

Authors:  Daniel Preckel; Roland von Känel
Journal:  Heartdrug       Date:  2004

3.  Lower-extremity functional electrical stimulation decreases platelet aggregation and blood coagulation in persons with chronic spinal cord injury: a pilot study.

Authors:  Nighat N Kahn; Susan P Feldman; William A Bauman
Journal:  J Spinal Cord Med       Date:  2010       Impact factor: 1.985

Review 4.  Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature.

Authors:  S L Senno; L Pechet
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

5.  Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus.

Authors:  Rehab S El-Hagracy; Gihan M Kamal; Inas M Sabry; Abeer A Saad; Nahla F Abou El Ezz; Hesham A R Nasr
Journal:  Oman Med J       Date:  2010-07

6.  Improvement of metabolic syndrome markers through altitude specific hiking vacations.

Authors:  S Greie; E Humpeler; H C Gunga; E Koralewski; A Klingler; M Mittermayr; D Fries; M Lechleitner; H Hoertnagl; G Hoffmann; G Strauss-Blasche; W Schobersberger
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

7.  Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study.

Authors:  Matteo Cesari; Stephen B Kritchevsky; Hal H Atkinson; Brenda W Penninx; Mauro Di Bari; Russell P Tracy; Marco Pahor
Journal:  Am Heart J       Date:  2009-02       Impact factor: 4.749

Review 8.  Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.

Authors:  William B Kannel
Journal:  Lipids       Date:  2005-12       Impact factor: 1.880

9.  Cardiovascular Disease Risk Assessment: Insights from Framingham.

Authors:  Ralph B D'Agostino; Michael J Pencina; Joseph M Massaro; Sean Coady
Journal:  Glob Heart       Date:  2013-03

10.  Association of tramadol with risk of myocardial infarction among patients with osteoarthritis.

Authors:  J Wei; M J Wood; M Dubreuil; G Tomasson; M R LaRochelle; C Zeng; N Lu; J Lin; H K Choi; G Lei; Y Zhang
Journal:  Osteoarthritis Cartilage       Date:  2019-10-16       Impact factor: 6.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.